Latest news with #Enfusion
Daily Mirror
10 hours ago
- Entertainment
- Daily Mirror
Andrew Tate responds to bold Roy Jones Jr boxing fight call-out
Despite having limited experience in the boxing ring, Tate is interested in going head-to-head with former multi-weight world champion Jones Jr Andrew Tate would jump at the the opportunity to fight Roy Jones Jr after the boxing icon revealed he would come out of retirement to face the controversial influencer. Tate, 38, had a successful kickboxing career during which he was a four-time world champion. Having enjoyed a glittering career in ISKA and Enfusion, the controversial influencer was forced to retire due to eye injuries that cost him his last few outings. In 2016, he was forced to quit against Ibrahim El Boustati. Since then, the 38-year-old has picked up wins against lower level opponents. Despite a brief stint in MMA and a respectable career in kickboxing, Tate is open to putting on the boxing gloves and trading leather with Jones Jr. During the peak of his powers, Jones Jr held four world titles in different weight categories: middleweight, super middleweight, light heavyweight and heavyweight. After seemingly calling it a day in 2018, Jones Jr returned to the ring two years later and took on Mike Tyson - with the pair going on to fight to an uninspiring draw in an exhibition bout. The 56-year-old make his professional comeback in 2023, but lost to former UFC champion Anthony Pettis. With Tate still training regularly, the American is open to a showdown with the 56-year-old. A spokesperson for the influencer said: "We would welcome the opportunity to initiate discussions regarding a high-profile fight between Roy Jones Jr and Andrew Tate, we are confident it would attract and captivate audiences worldwide." His comments came not long after Jones Jr declared he would be keen to make the blockbuster fight happen. Speaking to Slingo, he said: 'There are a lot of guys who fans would love to see me fight. Andrew Tate, he's very controversial, he knows his boxing stuff a little, he's been watching me a long time, he says some very good things and sometimes not. But I like his guts, that he is not afraid to express himself. That makes a boxer, someone not afraid to express themselves. I'd like to fight him, he has one of the bigger platforms and would make the biggest splash.' Tate learned this week that his trial of civil claims is due to be held months earlier than originally planned after a High Court judge said she was 'very keen to get on' with the case. Four women are suing Tate over allegations of sexual violence, including that he grabbed one by the throat on several occasions in 2015, assaulted her with a belt and pointed a gun at her face. Tate's barristers told an earlier court hearing that there was 'total denial of wrongdoing'. Boxing icon Jones also recently revealed he would be interested in a showdown with boxing star Tommy Fury. 'He's [Tommy Fury] calling out Mike Tyson, Jake [Paul] just had a pretty easy night with him, so people might think he would have an easy night with Tyson," he said. 'But, if you wanted to make a big splash, you could have come and seen Roy. That would have been a good fight. But if he wants Mike, he wants Mike. 'It would attract global attraction. If I came back it would be like when George Foreman and Muhammad Ali came back, because of who they were in their primes. Because of who I was in my prime it would attract global attention. People understand and hear that name, they get excited because they know of the name and what it brought to them, even if they saw a small glimpse of that and didn't get injured, they would be happy.'
Yahoo
17-04-2025
- Business
- Yahoo
Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration
BOISE, Idaho & CHICAGO, April 17, 2025--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) ("Clearwater") and Enfusion, Inc. (NYSE: ENFN) ("Enfusion") today announced the preliminary results of the elections made by Enfusion shareholders of record regarding the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction"). As previously disclosed, the deadline to have made such an election was 5:00 p.m. Eastern Time on April 16, 2025 (the "Election Deadline"). The parties expect to close the Transaction on April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions. As previously disclosed, on January 10, 2025, Enfusion, Clearwater, Enfusion Ltd. LLC ("Enfusion OpCo"), Poseidon Acquirer, Inc. (the "Acquirer"), Poseidon Merger Sub I, Inc. and Poseidon Merger Sub II, LLC entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement and as further described in the election materials and in the parties' definitive proxy statement/prospectus dated March 20, 2025, as supplemented by Supplement No. 1 thereto dated March 31, 2025 (as supplemented, the "Proxy Statement/Prospectus"), at the effective time of the Transaction (the "Effective Time"), each Enfusion shareholder will be entitled to receive, for each (i) share of Class A common stock of Enfusion outstanding as of immediately prior to the Effective Time, (ii) restricted stock unit of Enfusion that is vested as of immediately prior to the Effective Time or that will vest as a result of the consummation of the Transaction and (iii) limited liability company unit of Enfusion OpCo outstanding as of immediately prior to the Effective Time, in each case subject to proration according to the terms of the Merger Agreement to the extent any election is oversubscribed: (i) cash in an amount equal to $5.85 and (ii) a number of shares of Class A common stock of Clearwater equal to the Per Share Parent Stock Amount (as defined below) (the" Per Share Mixed Consideration"); a number of shares of Class A common stock of Clearwater equal to the Exchange Ratio (as defined below) (the "Per Share Stock Consideration"); or cash in an amount equal to the Aggregate Consideration Per Share (as defined below) (the "Per Share Cash Consideration"); and in each case, cash in lieu of any fractional shares of Class A common stock of Clearwater that such shareholder would otherwise be entitled to receive. The value paid per share of Enfusion Class A common stock will be equalized such that the value of the Merger Consideration will be substantially the same, regardless of which form of Merger Consideration is elected. As previously disclosed, the "Per Share Parent Stock Amount" is determined by dividing $5.40 by the volume-weighted average price (such price, the "Final Parent Stock Price") of one share of Clearwater Class A common stock for the ten-trading day period ending on (and including) the second to last trading day prior to (but not including) the closing date of the Transaction (the "Closing Date"); provided that (x) if the Final Parent Stock Price is less than or equal to $25.0133, then the Per Share Parent Stock Amount will be deemed to be 0.2159 and (y) if the Final Parent Stock Price is greater than or equal to $30.5718, then the Per Share Parent Stock Amount will be deemed to be 0.1766. The "Aggregate Consideration Per Share" will be determined by dividing the Aggregate Consideration by the total number of Enfusion Class A common stock and restricted stock units and Enfusion OpCo limited liability company units eligible to receive Merger Consideration (collectively, the "Eligible Shares"). The "Aggregate Consideration" will be determined as the sum of (i) a number of shares of Clearwater Class A common stock equal to the product of (x) the Per Share Parent Stock Amount multiplied by (y) the total number of Eligible Shares multiplied by (z) the Final Parent Stock Price and (ii) the product of $5.85 multiplied by the total number of Eligible Shares. The "Exchange Ratio" will be determined by dividing the Aggregate Consideration Per Share by the Final Parent Stock Price. Assuming the Transaction closes, as currently expected, on April 21, 2025, (A) the Final Parent Stock Price, based on the volume-weighted average price per share of Clearwater Class A common stock for the ten-trading day period ending on (and including) April 16, 2025, is $23.2440; and (B) the total number of Eligible Shares is expected to be 129,995,464 Eligible Shares. Based on the foregoing, and because the Final Parent Stock Price is less than $25.0133, (i) the Per Share Parent Stock Amount would be equal to 0.2159, (ii) the Aggregate Consideration would be equal to $1,412,840,049.03, (iii) the Aggregate Consideration Per Share would be equal to $10.87, (iv) the Per Share Cash Consideration would be equal to $10.87, and (v) the Exchange Ratio would be equal to 0.4676. In addition, assuming that the Transaction closes on April 21, 2025 and based on the expected Final Parent Stock Price and total number of Eligible Shares described above, CWAN and ENFN currently expect that the Corporate Mergers (as defined in the Proxy Statement/Prospectus) will qualify as a "reorganization" under Section 368(a) of the Internal Revenue Code of 1986, as amended, and that the conditions to consummating the Second Merger (as defined in the Proxy Statement/Prospectus) of Enfusion with and into the Acquirer, including the delivery of certain tax opinions related thereto, will be satisfied. Based on available information as of the Election Deadline, the preliminary results of the merger consideration election are as follows: Enfusion shareholders of record of approximately 45.5% of the outstanding Eligible Shares of Enfusion elected to receive the Per Share Mixed Consideration, subject to proration; Enfusion shareholders of record of approximately 6.1% of the outstanding Eligible Shares of Enfusion elected to receive the Per Share Stock Consideration; Enfusion shareholders of record of approximately 40.9% of the outstanding Eligible Shares of Enfusion elected to receive the Per Share Cash Consideration, subject to proration; and Enfusion shareholders of record of approximately 7.6% of the outstanding Eligible Shares of Enfusion did not make a valid election or did not deliver a valid election form prior to the Election Deadline will receive, in accordance with the terms of the Merger Agreement, the Per Share Stock Consideration. As the preliminary results indicate that the Per Share Cash Consideration option is oversubscribed, such election will be prorated pursuant to the terms set forth in the Merger Agreement. The foregoing results are preliminary only, and final certified results are not expected to be available until shortly before closing. After the final results of the election process are determined, the final merger consideration and the allocation of the merger consideration will be computed using the above-referenced formula set forth in the Merger Agreement. A more detailed description of the Merger Consideration and the proration procedures applicable to elections is contained in the Proxy Statement/Prospectus. Enfusion shareholders are urged to read the Proxy Statement/Prospectus carefully and in its entirety. Copies of the Proxy Statement/Prospectus may be obtained free of charge by following the instructions below under "Additional Information and Where to Find It." About Clearwater Analytics Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater's trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at About Enfusion Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 850 investment managers from 9 global offices spanning four continents. For more information, please visit Use of Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater's and Enfusion's management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater and/or Enfusion: the timing of the consummation of the acquisition and the ability to satisfy closing conditions, possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "aim," "may," "plan," "potential," "predict," "project," "seek," "should," "will," "would" or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater's and Enfusion's control, that may cause their actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to successfully close the acquisition, Clearwater's ability to successfully integrate the operations and technology of Enfusion with those of Clearwater, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion's clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under "Risk Factors" in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the "SEC") on February 26, 2025 and in Enfusion's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 3, 2025, as well as in other periodic reports filed by Clearwater and Enfusion with the SEC. These filings are available at and on Clearwater's website, and Enfusion's website, Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater's or Enfusion's expectations or beliefs as of any date subsequent to the time they are made. Each of Clearwater and Enfusion does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater or Enfusion. No Offer or Solicitation This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). Additional Information and Where to Find It In connection with the acquisition, Clearwater has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the shares of Clearwater's common stock to be issued pursuant to the acquisition. The Registration Statement was declared effective by the SEC on March 12, 2025 and Enfusion and Clearwater filed a definitive Proxy Statement/Prospectus on March 20, 2025. The Proxy Statement/Prospectus was mailed, on or about March 20, 2025, to Enfusion shareholders of record as of March 20, 2025. Each of Clearwater and Enfusion may also file other documents with the SEC regarding the acquisition. This press release is not a substitute for the Proxy Statement/Prospectus or any other document which Clearwater or Enfusion may file with the SEC in connection with the acquisition. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION, THE RISKS RELATED THERETO, AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus, and other relevant documents filed by Clearwater and Enfusion with the SEC (if and when available) through the website maintained by the SEC at Copies of documents filed with the SEC by Clearwater, including the Proxy Statement/Prospectus are also available free of charge from Clearwater's website at Copies of documents filed with the SEC by Enfusion, including the Proxy Statement/Prospectus are also available free of charge from Enfusion's website at Participants in the Solicitation Clearwater, Enfusion and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the Transaction. Information about Clearwater's directors and executive officers is available in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 26, 2025, the amendment to Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 7, 2025, and in the Proxy Statement/Prospectus. Information about the directors and executive officers of Enfusion is available in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 3, 2025, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 26, 2024, and in the Proxy Statement/Prospectus. Other information regarding the participants in the solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are or will be contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the Transaction when they become available. Investors should read the Proxy Statement/Prospectus carefully before making any voting or investment decisions. Copies of the documents filed with the SEC by Clearwater and Enfusion will be available free of charge through the website maintained by the SEC at Additionally, copies of documents filed with the SEC by Clearwater, including the Proxy Statement/Prospectus are available free of charge from Clearwater's website at and copies of documents filed with the SEC by Enfusion, including the Proxy Statement/Prospectus are available free of charge from Enfusion's website at View source version on Contacts Investor Contact for Clearwater Analytics Joon Park | +1 415-906-9242 | investors@ Investor Contact for Enfusion Bill Wright | investors@ Media Contact for Clearwater Analytics Claudia Cahill | +1 703-728-1221 | press@ Media Contact for Enfusion Mollie Applegate | media@
Yahoo
02-04-2025
- Business
- Yahoo
Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration
BOISE, Idaho & CHICAGO, April 02, 2025--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) ("Clearwater") and Enfusion, Inc. (NYSE: ENFN) ("Enfusion") today announced that the deadline for Enfusion shareholders of record to elect the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction") is 5:00 p.m. Eastern Time on April 16, 2025 (such deadline, as it may be extended, the "Election Deadline"). Enfusion shareholders who hold shares through a bank, broker or other nominee may be subject to an earlier election deadline and must carefully review and properly complete any election materials they received from their bank, broker or other nominee regarding how to make an election. The parties expect to close the Transaction on or about April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions. The election materials necessary for Enfusion shareholders of record to make an election as to the form of Merger Consideration they wish to receive have been sent to holders of record of Enfusion common stock as of March 20, 2025. Enfusion shareholders of record wishing to make an election must deliver properly completed election materials to Computershare Trust Company, N.A. by the Election Deadline. As previously disclosed, on January 10, 2025, Enfusion, Clearwater, Enfusion Ltd. LLC ("Enfusion OpCo"), Poseidon Acquirer, Inc., Poseidon Merger Sub I, Inc. and Poseidon Merger Sub II, LLC entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement and as further described in the election materials and in the parties' definitive proxy statement/prospectus dated March 20, 2025, as supplemented by Supplement No. 1 thereto dated March 31, 2025 (the "Proxy Statement/Prospectus"), at the effective time of the Transaction (the "Effective Time"), each Enfusion shareholder will be entitled to receive, for each (i) share of Class A common stock of Enfusion outstanding as of immediately prior to the Effective Time, (ii) restricted stock unit of Enfusion that is vested as of immediately prior to the Effective Time or that will vest as a result of the consummation of the Transaction and (iii) limited liability company unit of Enfusion OpCo outstanding as of immediately prior to the Effective Time, in each case subject to proration according to the terms of the Merger Agreement to the extent any election is oversubscribed: (i) cash in an amount equal to $5.85 and (ii) a number of shares of Class A common stock of Clearwater equal to the Per Share Parent Stock Amount (as defined below); a number of shares of Class A common stock of Clearwater equal to the Exchange Ratio (as defined below); or cash in an amount equal to the Aggregate Consideration Per Share (as defined below); and in each case, cash in lieu of any fractional shares of Class A common stock of Clearwater that such shareholder would otherwise be entitled to receive. The value paid per share of Enfusion Class A common stock will be equalized such that the value of the Merger Consideration will be substantially the same, regardless of which form of Merger Consideration is elected. The "Per Share Parent Stock Amount" will be determined by dividing $5.40 by the volume-weighted average price (such price, the "Final Parent Stock Price") of one share of Clearwater Class A common stock for the ten-trading day period ending on (and including) the second to last trading day prior to (but not including) the closing date of the Transaction (the "Closing Date"); provided that (x) if the Final Parent Stock Price is less than or equal to $25.0133, then the Per Share Parent Stock Amount will be deemed to be 0.2159 and (y) if the Final Parent Stock Price is greater than or equal to $30.5718, then the Per Share Parent Stock Amount will be deemed to be 0.1766. The "Aggregate Consideration Per Share" will be determined by dividing the Aggregate Consideration by the total number of Enfusion Class A common stock and restricted stock units and Enfusion OpCo limited liability company units eligible to receive Merger Consideration (collectively, the "Eligible Shares"). The "Aggregate Consideration" will be determined as the sum of (i) a number of shares of Clearwater Class A common stock equal to the product of (x) the Per Share Parent Stock Amount multiplied by (y) the total number of Eligible Shares multiplied by (z) the Final Parent Stock Price and (ii) the product of $5.85 multiplied by the total number of Eligible Shares. The "Exchange Ratio" will be determined by dividing the Aggregate Consideration Per Share by the Final Parent Stock Price. Enfusion shareholders with questions regarding the election materials or the election process should contact Innisfree M&A Incorporated, the information agent for the election, at (877) 750-0637 or their bank, broker or other nominee, as applicable, as soon as possible. A more detailed description of the Merger Consideration and the proration procedures applicable to elections is contained in the Proxy Statement/Prospectus. Enfusion stockholders are urged to read the Proxy Statement/Prospectus carefully and in its entirety. Copies of the Proxy Statement/Prospectus may be obtained free of charge by following the instructions below under "Additional Information and Where to Find It." About Clearwater Analytics Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater's trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at About Enfusion Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 850 investment managers from 9 global offices spanning four continents. For more information, please visit Use of Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater's and Enfusion's management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater and/or Enfusion: the timing of the consummation of the acquisition and the ability to satisfy closing conditions, possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "aim," "may," "plan," "potential," "predict," "project," "seek," "should," "will," "would" or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater's and Enfusion's control, that may cause their actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to successfully close the acquisition, Clearwater's ability to successfully integrate the operations and technology of Enfusion with those of Clearwater, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion's clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under "Risk Factors" in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the "SEC") on February 26, 2025 and in Enfusion's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 3, 2025, as well as in other periodic reports filed by Clearwater and Enfusion with the SEC. These filings are available at and on Clearwater's website, and Enfusion's website, Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater's or Enfusion's expectations or beliefs as of any date subsequent to the time they are made. Each of Clearwater and Enfusion does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater or Enfusion. No Offer or Solicitation This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). Additional Information and Where to Find It In connection with the acquisition, Clearwater has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the shares of Clearwater's common stock to be issued pursuant to the acquisition. The Registration Statement was declared effective by the SEC on March 12, 2025 and Enfusion and Clearwater filed a definitive Proxy Statement/Prospectus on March 20, 2025. The Proxy Statement/Prospectus was mailed, on or about March 20, 2025, to Enfusion shareholders of record as of March 20, 2025. Each of Clearwater and Enfusion may also file other documents with the SEC regarding the acquisition. This press release is not a substitute for the Proxy Statement/Prospectus or any other document which Clearwater or Enfusion may file with the SEC in connection with the acquisition. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION, THE RISKS RELATED THERETO, AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus, and other relevant documents filed by Clearwater and Enfusion with the SEC (if and when available) through the website maintained by the SEC at Copies of documents filed with the SEC by Clearwater, including the Proxy Statement/Prospectus are also available free of charge from Clearwater's website at Copies of documents filed with the SEC by Enfusion, including the Proxy Statement/Prospectus are also available free of charge from Enfusion's website at Participants in the Solicitation Clearwater, Enfusion and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the Transaction. Information about Clearwater's directors and executive officers is available in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 26, 2025, the amendment to Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 7, 2025, and in the Proxy Statement/Prospectus. Information about the directors and executive officers of Enfusion is available in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 3, 2025, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 26, 2024, and in the Proxy Statement/Prospectus. Other information regarding the participants in the solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are or will be contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the Transaction when they become available. Investors should read the Proxy Statement/Prospectus carefully before making any voting or investment decisions. Copies of the documents filed with the SEC by Clearwater and Enfusion will be available free of charge through the website maintained by the SEC at Additionally, copies of documents filed with the SEC by Clearwater, including the Proxy Statement/Prospectus are available free of charge from Clearwater's website at and copies of documents filed with the SEC by Enfusion, including the Proxy Statement/Prospectus are available free of charge from Enfusion's website at View source version on Contacts Investor Contact for Clearwater Analytics Joon Park | +1 415-906-9242 | investors@ Investor Contact for Enfusion Bill Wright | investors@ Media Contact for Clearwater Analytics Claudia Cahill | +1 703-728-1221 | press@ Media Contact for Enfusion Mollie Applegate | media@ Sign in to access your portfolio
Associated Press
12-03-2025
- Business
- Associated Press
Clearwater Analytics to Acquire Beacon and Blackstone's Bistro to Deliver Investment Intelligence Across Private Markets
Clearwater Analytics (NYSE: CWAN) ('Clearwater') today announced two strategic acquisitions, marking a major step toward transforming investment management technology. Clearwater has entered into a definitive agreement to acquire Beacon, a next-generation leader for cross-asset class modeling and risk analytics for derivatives, private credit and debt, structured products and other alternative assets. Integrated with Wilshire's equities and fixed income risk capabilities, this powerful engine enables portfolio modeling and risk management, addressing the growing focus on private and alternative assets. With institutional investors now allocating nearly 20% of their portfolios to alternatives, the need for sophisticated risk solutions has never been greater. Beacon's platform provides complete transparency, openness and extensibility and is used by some of the most sophisticated financial firms including PIMCO, Blackstone, multi-strategy hedge funds, insurance asset managers, banks and energy traders. Clearwater also announced a definitive asset purchase agreement to acquire Bistro, Blackstone's proprietary portfolio visualization software platform built for Blackstone's Credit & Insurance business. As the world's largest alternative asset manager, Blackstone developed Bistro to support the growth of its insurance clients and provide a comprehensive view of private credit portfolios, including asset analytics, client reporting, and risk management insights. Two key foundational pillars of the Bistro platform are Clearwater and Beacon, and tight integration with these platforms has been—and continues to be—a core architectural construct. 'With this combination, Chief Investment and Chief Risk Officers will have a unified, real-time view of their entire portfolio—from public equities and private credit to structured products and alternatives—all in a single, cloud-native platform. The Clearwater platform will allow them to drill down and comprehensively understand their exposure to a company, industry or geography across all their investments, public and private. That will, in turn, allow them to model their entire portfolio, evaluate cash flows and understand risk. Add to that the industry-leading pre-trade capabilities of the Enfusion platform, and the industry will have a true front-to-back platform, enhancing their ability to make better investment decisions,' said Sandeep Sahai, CEO at Clearwater Analytics. 'This is an incredible moment—not just for Beacon, but for the entire industry,' said Kirat Singh, CEO of Beacon. 'Our platform is already integrated with Clearwater and Enfusion at many of our shared clients, delivering best-in-class risk, performance and pre-trade functionality. By bringing these platforms together, along with Blackstone's Bistro, we're creating something truly industry-leading—giving institutional investors complete transparency across front office, pre-trade, risk and accounting. We believe no one else can offer this level of depth, and I couldn't be more excited for what's ahead.' 'Technology is critical to everything we do, including how we interface with key investors who are broadening their exposure to private credit assets. We built the Bistro platform to address a need we saw in the market both for ourselves and our clients to have a more advanced credit portfolio insights platform. Clearwater has an exciting opportunity to continue evolving this core infrastructure platform for the credit asset management industry and we look forward to helping them build something that creates enduring value,' said John Stecher, Chief Technology Officer of Blackstone. Michael Chae, Blackstone Vice Chairman & Chief Financial Officer, added: 'The culture of innovation at Blackstone extends across how we develop both investment and operational solutions, and the value creation represented by Bistro is a reflection of that.' 'PIMCO has had a strategic partnership and minority stake in Beacon since 2018 and is highly supportive of the combination with Clearwater. Our partnership with Beacon has enabled us to accelerate the development of market-leading risk and analytics tools on behalf of our clients. We are excited to build upon this long-standing partnership with Clearwater and to explore even more opportunities which create value for our clients globally,' said John Kirkowski, Managing Director and Chief Financial Officer of PIMCO. For years, institutional investors have been forced to choose between powerful analytics and operational efficiency—relying on disparate, rigid, legacy platforms that create endless cycles of upgrades, manual reconciliations, and fragmented data spread across spreadsheets and disconnected systems. These inefficiencies slow decision-making, increase operational risk, and make it difficult to gain a unified view of portfolios. Clearwater is eliminating these challenges with a true front-to-back, public-to-private market platform – a seamless integration of Clearwater's industry-leading data and accounting platform with Beacon's cross-asset risk modeling, Bistro's alternative asset intelligence, and Enfusion's front-office capabilities. By breaking down data silos across the front, middle, and back-office, this platform will provide a single source of truth for investment execution, accounting, risk management, compliance, regulatory reporting, and analytics across all asset classes. For the first time, institutional investors can better see, analyze, and act across public and private markets in near real-time—without the operational bottlenecks of legacy systems. Clearwater's platform and architecture give us the opportunity to deliver on this promise. While seamlessly integrating these modern, cloud-native technology platforms will benefit clients immediately, our vision is much bolder. We aim to create a singular data ingestion, aggregation and reconciliation engine for use across all these business functions and platforms. The Clearwater platform already has the data architecture to support that today and processes over $8.8 trillion every day across asset classes. This will form the foundation and is, we believe, a game changer. Another foundational element is the pursuit of a single security master for use across these platforms. Clearwater's current architecture uses that approach at scale and has a single security master for all its 1,450+ clients. Extending that to include the needs of these additional platforms will be transformational for the industry. Having a single security master is at the core of creating a true front to back platform and will, in our opinion, be a game changer. The Clearwater platform will utilize a single security master and a unified data plane across all asset classes, business functions, and clients—including portfolio modeling, pre-trade compliance, trade execution, risk and performance management, accounting, post-trade compliance, and regulatory reporting. We believe this has the power to transform portfolio transparency and dramatically enhance the speed of decision-making for investment managers. With real-time data flow, decision-making accelerates, while data-driven insights, real-time benchmarking, and scenario analysis empower investment teams to act confidently. What This Means for Institutional Investors For insurance companies and asset owners, these acquisitions represent a fully integrated technology stack for investment management that combines pre-trade, post-trade and risk all in one platform. It will bring all their public and private assets into a single analytics framework, obviating the need for constant upgrades, endless reconciliation and error-prone manual processing. This platform will also enable efficient asset liability matching and regulatory reporting and lower the cost of doing business. For asset managers, this will mean eliminating inefficiencies in managing private credit, real estate debt, structured products and alternative investments. Clearwater will be the only SaaS platform capable of providing a complete, real-time understanding of exposures, cash flow dynamics and risk correlations across strategies, geographies and asset types. Client reporting that includes a comprehensive view of all their public and private assets and scenario modeling will be dramatically enhanced. Clearwater's vision goes beyond solving today's challenges—its open architecture, single security master, single data plane and ability to do benchmarking provides the foundation for the creation of marketplaces, both commercial and technology. Firms will be able to offer proprietary models for use by market participants. Other firms could offer regulatory reporting enhancements for different countries and tax regimes. Clearwater will acquire Beacon for an aggregate purchase price of approximately $560m, 60% of which will be paid in cash, with the remainder to be paid in shares of Clearwater Class A common stock valued at approximately $30.05 per share. With ARR of approximately $44m at the end of 2024, this platform has scale and market acceptance as a leading risk and modeling platform. The purchase price for the Bistro software is $125m, of which $10m will be paid in cash and the remainder will be paid in shares of Class A common stock, valued at $30.00 per share. This transaction represents the purchase of a platform developed by Blackstone. Clearwater will use the proceeds from its previously committed $800m Term Loan B, cash on hand, and a portion of its $200m revolving line of credit to fund the acquisitions of Beacon and Bistro and the previously announced acquisition of Enfusion. 'These transactions bring the critical IP needed to build a disruptive, end-to-end platform for the investment management industry. Integrating these platforms into a single, seamless solution will require intense focus and execution over the next year or two, but I'm confident in our ability to deliver. As we complete this work, we expect our customers to be completely delighted,' added Sahai. Conference Call and Webcast Clearwater Analytics will host an investor conference call to discuss the transaction on March 12, 2025, at 8:30 a.m. ET. A live webcast of the call will be accessible via Clearwater's Investor Relations website at A replay of the webcast will also be available on Clearwater's Investor Relations website shortly after the call. Advisors Kirkland & Ellis LLP is serving as legal advisor to Clearwater in both transactions. Orrick, Herrington & Sutcliffe LLP is serving as legal advisor to Beacon. Simpson Thacher & Bartlett LLP is serving as legal advisor to Blackstone. Broadhaven Capital Partners served as financial advisor to Beacon. About Clearwater Analytics Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater's trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at About Beacon Beacon enables front-office, risk, and investment teams to manage risk, focus on developing strategies, and capture market opportunities using our cross-asset trading and risk management models and applications. Beacon's unified, cloud-native platform and shared code repository give quantitative developers the flexibility to integrate with existing in-house and third-party systems and data providers to rapidly build, test, and deploy custom risk models and analytics. About Blackstone Blackstone is the world's largest alternative asset manager. We seek to deliver compelling returns for institutional and individual investors by strengthening the companies in which we invest. Our more than $1.1 trillion in assets under management include global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries and hedge funds. Further information is available at Follow @blackstone on LinkedIn, X (Twitter), and Instagram. Use of Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater's management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater, Enfusion, Beacon and/or Bistro (the acquisitions of Enfusion, Beacon and Bistro are referred to herein as the 'Referenced Acquisitions'): the timing of the consummation of any of the Referenced Acquisitions and the ability to satisfy closing conditions, possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'seek,' 'should,' 'will,' 'would' or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater's control, that may cause its actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to successfully close the Referenced Acquisitions, Clearwater's ability to successfully integrate the operations and technology of the Referenced Acquisitions with those of Clearwater and to obtain third party data rights, retain and incentivize the employees of Enfusion and Beacon following the close of the acquisition, retain clients in the case of the acquisition of Enfusion and Beacon, repay debt to be incurred in connection with the Referenced Acquisitions and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the Referenced Acquisitions may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under 'Risk Factors' in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the 'SEC') on February 26, 2025, as well as in other periodic reports filed by Clearwater with the SEC. These filings are available at and on Clearwater's website, Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater's expectations or beliefs as of any date subsequent to the time they are made. Clearwater does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater. SOURCE: Clearwater Analytics Copyright Business Wire 2025. PUB: 03/12/2025 06:30 AM/DISC: 03/12/2025 06:30 AM
Yahoo
27-02-2025
- Business
- Yahoo
Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion
BOISE, Idaho, February 27, 2025--(BUSINESS WIRE)--Clearwater Analytics Holdings, Inc. (NYSE: CWAN) ("Clearwater" or the "Company"), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and Enfusion, Inc. (NYSE: ENFN) ("Enfusion"), a leader in software-as-a-service solutions for the investment management and hedge fund industry, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act"), in connection with Clearwater's previously announced proposed acquisition of Enfusion. The expiration of the waiting period occurred at 11:59 p.m. on February 24, 2025. The expiration of the waiting period under the HSR Act satisfies one of the closing conditions for the completion of the transaction. The transaction is expected to close in the second quarter of 2025, subject to the satisfaction or waiver of customary closing conditions including the receipt of Enfusion shareholder approval. About Clearwater Analytics Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater's trusted data to drive efficient, scalable investing on more than $8.8 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at About Enfusion Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration boosting agility and powering growth. Enfusion partners with over 850 investment managers from 9 global offices spanning four continents. For more information, please visit Use of Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater's and Enfusion's management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater and/or Enfusion: the timing of the consummation of the acquisition and the ability to satisfy closing conditions, possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "aim," "may," "plan," "potential," "predict," "project," "seek," "should," "will," "would" or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater's and Enfusion's control, that may cause their actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to successfully close the acquisition, Clearwater's ability to successfully integrate the operations and technology of Enfusion with those of Clearwater, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion's clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, as well as other risks and uncertainties discussed under "Risk Factors" in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the "SEC") on February 26, 2025 and in Enfusion's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024, those discussed under "Risk Factors" in Enfusion's Annual Report on Form 10-K for the year ended December 31, 2024 that will be filed following this press release, as well as in other periodic reports filed by Clearwater and Enfusion with the SEC. These filings are available at and on Clearwater's website, and Enfusion's website, Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater's or Enfusion's expectations or beliefs as of any date subsequent to the time they are made. Each of Clearwater and Enfusion does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater or Enfusion. No Offer or Solicitation This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). Additional Information and Where to Find It In connection with the acquisition, Clearwater has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the shares of Clearwater's common stock to be issued pursuant to the acquisition, which constitutes a prospectus of Clearwater and a proxy statement of Enfusion (the "proxy statement/prospectus"). Each of Clearwater and Enfusion may also file other documents with the SEC regarding the acquisition. This press release is not a substitute for the Registration Statement, proxy statement/prospectus or any other document which Clearwater or Enfusion may file with the SEC in connection with the acquisition. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION, THE RISKS RELATED THERETO, AND RELATED MATTERS. After the Registration Statement has been declared effective, the definitive proxy statement/prospectus (if and when available) will be mailed to Enfusion's security holders. Investors and security holders will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended or supplemented from time to time, and other relevant documents filed by Clearwater and Enfusion with the SEC (if and when available) through the website maintained by the SEC at Copies of documents filed with the SEC by Clearwater, including the proxy statement/prospectus will be available free of charge from Clearwater's website at Copies of documents filed with the SEC by Enfusion, including the proxy statement/prospectus will be available free of charge from Enfusion's website at Participants in the Solicitation Clearwater, Enfusion and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the Transaction. Information about Clearwater's directors and executive officers is available in Clearwater's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 26, 2025, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 29, 2024, and in the proxy statement/prospectus. Information about the directors and executive officers of Enfusion is available in its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 12, 2024, its Annual Report on Form 10-K for the year ended December 31, 2024 that will be filed following this press release, its definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April 26, 2024, and in the proxy statement/prospectus. Other information regarding the participants in the solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are or will be contained in the Registration Statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Transaction when they become available. Investors should read the proxy statement/prospectus carefully before making any voting or investment decisions. Copies of the documents filed with the SEC by Clearwater and Enfusion will be available free of charge through the website maintained by the SEC at Additionally, copies of documents filed with the SEC by Clearwater, including the proxy statement/prospectus will be available free of charge from Clearwater's website at and copies of documents filed with the SEC by Enfusion, including the proxy statement/prospectus will be available free of charge from Enfusion's website at View source version on Contacts Investor Contact for Clearwater Analytics Joon Park | +1 415-906-9242 | investors@ Investor Contact for Enfusion Bill Wright | investors@ Media Contact for Clearwater Analytics Claudia Cahill | +1 703-728-1221 | press@ Media Contact for Enfusion Mollie Applegate | media@ Sign in to access your portfolio
